99mTc-3PRGD2
Showing 1 - 25 of >10,000
Lung Cancer Metastatic Trial in China (99mTc-3PRGD2)
Completed
- Lung Cancer Metastatic
- 99mTc-3PRGD2
-
Beijing, Beijing, China
- +3 more
Apr 25, 2022
Esophageal Cancer Trial in Fuzhou (99mTc-3PRGD2)
Completed
- Esophageal Cancer
- 99mTc-3PRGD2
-
Fuzhou, Fujian, ChinaDepartment of Nuclear Medicine, First Affiliated Hospital of Fuj
Jul 30, 2020
Breast Cancer Trial in Fuzhou (99mTc-3PRGD2)
Completed
- Breast Cancer
- 99mTc-3PRGD2
-
Fuzhou, Fujian, ChinaDepartment of Nuclear Medicine, First Affiliated Hospital of Fuj
Jul 30, 2020
Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)
Enrolling by invitation
- Breast Cancer Female
-
Tomsk, Russian FederationOlga
Jun 19, 2023
Prostate Cancer Trial ([99mTc]Tc-PSMA-T4)
Not yet recruiting
- Prostate Cancer
- [99mTc]Tc-PSMA-T4
- (no location specified)
Apr 26, 2023
Solid Tumor, Adult Trial in Tomsk (Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1)
Enrolling by invitation
- Solid Tumor, Adult
- Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
-
Tomsk, Russian FederationTomskNRMC
Jan 23, 2023
99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast
Enrolling by invitation
- Breast Cancer Female
- 99mTc-DARPinG3 SPECT/CT
-
Tomsk, Russian FederationRussia Tomsk NRMC
Jan 23, 2023
Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)
Recruiting
- Breast Cancer Female
-
Tomsk, Russian FederationTomsk NRMC
May 12, 2022
Breast Cancer Trial in Beijing (99mTc-MY6349 SPECT/CT scan)
Recruiting
- Breast Cancer
- 99mTc-MY6349 SPECT/CT scan
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 24, 2023
Molecular Imaging in HER2-positive Breast Cancer During
Enrolling by invitation
- HER2-positive Breast Cancer
- Female
-
Tomsk, Russian Federation
- +1 more
Jun 7, 2022
Healthy Trial in Beijing (99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2))
Completed
- Healthy
- 99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)
-
Beijing, ChinaPeking Union Medical College Hospital
Aug 7, 2019
Breast Cancer Trial in Beijing (99mTc-MIRC213)
Recruiting
- Breast Cancer
-
Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Nov 18, 2022
Non Small Cell Lung Cancer Trial in Beijing (1.11 GBq of 177Lu-AB-3PRGD2)
Recruiting
- Non Small Cell Lung Cancer
- 1.11 GBq of 177Lu-AB-3PRGD2
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 15, 2021
Simplification of Low Level Internal Dosimetry
Recruiting
- Exposure to Medical Diagnostic Radiation
- 18-F FDG PET/CT dosimetry scans and measurements
- +6 more
-
Sutton, Surrey, United KingdomThe Royal Marsden NHS Foundation Trust
Dec 7, 2021
99mTc-ADAPT6-based HER2 Imaging in Breast Cancer
Completed
- Breast Cancer
- SPECT
-
Tomsk, Russian FederationTomskNRMC
Mar 30, 2021
Microvascular Injury and Distal Thrombosis in COVID-19
Completed
- SARS-CoV-2 Infection
- lung ventilation/perfusion scintigraphy
-
Monaco, MonacoCentre Hospitalier Princesse Grace
Mar 8, 2022
Breast Cancer, Radiotoxicity Trial in Shanghai (Injection of 99mTc-NM-02, Injection of 188Re-NM-02)
Unknown status
- Breast Cancer
- Radiotoxicity
- Injection of 99mTc-NM-02
- Injection of 188Re-NM-02
-
Shanghai, Shanghai, ChinaShanghai General Hospital
Dec 14, 2020
Breast Cancer Trial in Shanghai (Injection of 99mTc-NM-02)
Unknown status
- Breast Cancer
- Injection of 99mTc-NM-02
-
Shanghai, Shanghai, ChinaShanghai General Hospital
Dec 6, 2020
Lung Cancer Trial in Decatur ((99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging)
Active, not recruiting
- Lung Cancer
- (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
- 18 F FDG followed by PET/CT imaging
-
Decatur, IllinoisDecatur Memorial Hospital
Jan 28, 2021
Rheumatoid Arthritis Trial in Los Angeles, Chicago, London (Tc 99m tilmanocept)
Recruiting
- Rheumatoid Arthritis
- Tc 99m tilmanocept
-
Los Angeles, California
- +3 more
Sep 13, 2022